The ability to move enables many bacteria to reach a specific niche or to leave hostile environments. The bacterium Mycoplasma gallisepticum is a poultry pathogen that is capable of gliding over solid surfaces. Scientists at the University of Veterinary Medicine, Vienna have now identified the proteins responsible for this gliding mechanism. Interrupting the gliding mechanism could be a way to make the bacteria less virulent, but it could also help in the development of vaccines against the pathogen. The results were published in the journal Veterinary Research.
Mycoplasma gallisepticum causes chronic respiratory disease in birds. The illness particularly affects domestic chicken and turkey flocks. The bacteria are especially life-threatening for the animals when they occur in combination with other infections. In order to control the spread of the disease, poultry farms in the EU must be proven free from Mycoplasma gallisepticum or face being closed.
Mycoplasma gallisepticum is related to the human pathogen Mycoplasma pneumoniae, the causative agent of human bronchitis and pneumonia. Mycoplasmas are among the world’s smallest microorganisms. Scientists even speak of degenerative bacteria. Over the course of evolution, mycoplasmas have thrown most of their genetic material over board, resulting in one of the smallest bacterial genomes. This is what makes them such efficiently adapted pathogens in humans and animals.
At least three proteins responsible for the gliding mechanism
The gliding motility of M. gallisepticum was first observed in the 1960s. However, it has so far been unclear how exactly the gliding mechanism works and which proteins make gliding possible. First author Ivana Indikova and study director Michael Szostak of the Institute of Microbiology at the Vetmeduni Vienna have now found that gliding requires the proteins GapA, CrmA and Mgc2. “If the bacteria are missing one of these three proteins, they are no longer able to move. We want to know if non-motile mycoplasmas are less infectious. If that were the case, we could target the motility genes to turn them off and so render the bacteria harmless,” Szostak explains.
Gliding motility could even contribute to the ability of mycoplasmas to invade and traverse body cells. This could allow them to safely evade the body’s immune system and the infection could spread efficiently through the host body.
The experts can also imagine the development of a vaccine. “Non-motile and non-pathogenic bacteria could form the basis for a new vaccine which the immune system could recognize and fight without causing any illness in the organism,” explains Szostak.
Do gliding mycoplasmas go against the flow?
The ability to move thus gives the pathogens certain advantages. It remains unknown, however, which stimuli M. gallisepticum responds to when gliding. Szostak suspects: “Most mycoplasmas cannot glide. Gliding species have so far been found only in the respiratory and genital tracts – places in which there is a directional mucus flow. We believe that the gliding bacteria possibly move against this flow in order to reach deeper-lying regions of the body. We are currently planning further experiments to attempt to answer this question.”